TherapeuticsMD (NASDAQ:TXMD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Friday.
According to Zacks, “TherapeuticsMD, Inc. is a specialty pharmaceutical company focused on creating branded prescription, generic prescription and over-the-counter products targeted exclusively for women. It is developing three advanced hormone replacement products designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies. TherapeuticsMD, Inc. is based in Boca Raton, Florida. “
Other equities analysts also recently issued reports about the stock. ValuEngine upgraded shares of TherapeuticsMD from a “hold” rating to a “buy” rating in a research note on Friday, September 21st. Oppenheimer set a $14.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, September 26th. Cantor Fitzgerald set a $27.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Thursday, September 27th. BidaskClub upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a research note on Friday, September 7th. Finally, JPMorgan Chase & Co. set a $11.00 price objective on shares of TherapeuticsMD and gave the company a “buy” rating in a research note on Wednesday, August 15th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average target price of $13.88.
TXMD stock traded up $0.07 during mid-day trading on Friday, reaching $5.04. The company had a trading volume of 70,982 shares, compared to its average volume of 3,396,419. The company has a debt-to-equity ratio of 0.94, a current ratio of 7.88 and a quick ratio of 7.79. The company has a market capitalization of $1.14 billion, a P/E ratio of -13.73 and a beta of 1.40. TherapeuticsMD has a 12 month low of $4.30 and a 12 month high of $7.66.
TherapeuticsMD (NASDAQ:TXMD) last issued its earnings results on Monday, July 30th. The company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.03). The company had revenue of $3.80 million during the quarter, compared to the consensus estimate of $4.23 million. TherapeuticsMD had a negative return on equity of 80.75% and a negative net margin of 582.86%. TherapeuticsMD’s revenue was down 11.6% on a year-over-year basis. During the same quarter in the prior year, the company earned ($0.10) earnings per share. On average, research analysts expect that TherapeuticsMD will post -0.63 EPS for the current fiscal year.
In other TherapeuticsMD news, insider John C.K. Iv Milligan sold 250,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 11th. The shares were sold at an average price of $6.10, for a total value of $1,525,000.00. Following the completion of the sale, the insider now directly owns 1,597,419 shares in the company, valued at $9,744,255.90. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Robert G. Finizio sold 184,000 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The shares were sold at an average price of $6.24, for a total transaction of $1,148,160.00. Following the completion of the sale, the chief executive officer now owns 18,485,559 shares of the company’s stock, valued at $115,349,888.16. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 2,158,800 shares of company stock worth $12,946,562. Insiders own 22.85% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Managed Account Services Inc. acquired a new stake in TherapeuticsMD in the third quarter valued at approximately $117,000. Fox Run Management L.L.C. acquired a new stake in TherapeuticsMD in the second quarter valued at approximately $121,000. Xact Kapitalforvaltning AB boosted its stake in TherapeuticsMD by 96.3% in the first quarter. Xact Kapitalforvaltning AB now owns 31,800 shares of the company’s stock valued at $155,000 after acquiring an additional 15,600 shares in the last quarter. Affiance Financial LLC acquired a new stake in TherapeuticsMD in the second quarter valued at approximately $156,000. Finally, Barclays PLC boosted its stake in TherapeuticsMD by 33,787.3% in the first quarter. Barclays PLC now owns 37,276 shares of the company’s stock valued at $182,000 after acquiring an additional 37,166 shares in the last quarter. Institutional investors own 66.13% of the company’s stock.
TherapeuticsMD, Inc operates as a women's health care product company. Its pipeline of hormone therapy drug candidates include TX-001HR, a combination of estradiol and progesterone drug candidate under clinical trials for the treatment of moderate to severe vasomotor symptoms due to menopause; TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil; and TX-004HR, an applicator-free vaginal estradiol softgel drug candidate for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy in post-menopausal women with vaginal linings that do not receive enough estrogen.
Recommended Story: What Does Beta Mean In Stock Selection
Get a free copy of the Zacks research report on TherapeuticsMD (TXMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.